Resources

Taking omega-3 fatty-acid supplements for nearly five years failed to reduce the incidence of CVD mortality, MI, stroke, unstable angina, revascularization, CHF hospitalizations, and resuscitated cardiac arrest, report investigators….

New evidence suggests that increased intake of certain vitamins, including B vitamins, may play a role in the increased prevalence of obesity in recent years….

Although glucagon-like peptide-1 (GLP-1) is highly biologically active following intravenous or subcutaneous injection, a non-injectable alternative for activating GLP-1 receptor signaling would clearly be desirable. Studies by Gutniak, Ahren and colleagues in Sweden have shown that GLP-1 formulated in buccal tablets is absorbed into the circulation and lowers blood glucose …

John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …

John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …

Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format: Obesity …

Richard S. Beaser, MD This week’s excerpt covers the following topics: Knowing the options for treatment Determining medication selection Clinical markers for the dominant underlying pathophysiology The three stages to glucose patterns

Pendiq  The next generation in insulin pens comes to Europe first as they use pens 5-8 times more than the U.S. does. The pen can deliver dosages with a minimum dose of 2.0 units and increments of 0.1Units can be made. The Pendiq insulin pen is operated with common 3ml insulin …